News >

Effectiveness of Adriamycin Questioned in the Treatment of Patients With HER2-Positive Breast Cancer

Ben Leach
Published: Friday, Oct 07, 2011

Adriamycin According to a study published this week in The New England Journal of Medicine, HER2-positive women can be effectively treated with Herceptin (trastuzumab injection) without the use of Adriamycin, a drug that raises the risk of permanent heart damage. Herceptin—a molecularly targeted drug that is designed for HER2-positive patients with early-stage breast cancer, who comprise about 20% to 25% of new breast cancer diagnoses each year—when combined with carboplatin and Taxotere as chemotherapy, appears to increase survival of patients who are at risk of developing a particularly aggressive form of the disease.

The study was sponsored by Sanofi-Aventis and Genentech and was funded in part by the Department of Defense, the Revlon/UCLA Women’s Cancer Research Program, the US Army Medical Research and Development Command, the National Cancer Institute, the California Breast Cancer Research Program, and the Peter and Denise Wittich Family Project for Emerging Therapies in Breast Cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication
x